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Epstein-Barr virus (EBV; human herpesvirus 4) poses major clinical problems worldwide. Following pri-
mary infection, EBV enters a form of long-lived latency in B lymphocytes, expressing few viral genes, and it
persists for the lifetime of the host with sporadic bursts of viral replication. The switch between latency and
replication is governed by the action of a multifunctional viral protein Zta (also called BZLF1, ZEBRA, and
Z). Using a global proteomic approach, we identified a host DNA damage repair protein that specifically
interacts with Zta: 53BP1. 53BP1 is intimately connected with the ATM signal transduction pathway, which is
activated during EBV replication. The interaction of 53BP1 with Zta requires the C-terminal ends of both
proteins. A series of Zta mutants that show a wild-type ability to perform basic functions of Zta, such as dimer
formation, interaction with DNA, and the transactivation of viral genes, were shown to have lost the ability to
induce the viral lytic cycle. Each of these mutants also is compromised in the C-terminal region for interaction
with 53BP1. In addition, the knockdown of 53BP1 expression reduced viral replication, suggesting that the
association between Zta and 53BP1 is involved in the viral replication cycle.
The Epstein-Barr virus (EBV) life cycle is divided tempo-
rally into two phases, latency and the lytic cycle. Following the
infection of epithelial cells of the oropharynx, EBV enters the
lytic cycle, where the expression of approximately 80 genes and
numerous rounds of genome replication occur, culminating in
the production of infectious virions. The infection of B lym-
phocytes results in the establishment of viral latency with a
restricted gene expression pattern; these cells sporadically en-
ter the lytic cycle and reproduce infectious virus (27, 53).
The EBV gene BZLF1 has been associated specifically with
the disruption of latency (reviewed in references 34 and 50).
This gene encodes the protein Zta (ZEBRA, BZLF1, Z),
which has an undisputed role in activating the viral lytic cycle.
Not only is the enforced expression of Zta in cells harboring
the latent virus able to induce the viral lytic cycle, but a mutant
virus where BZLF1 has been inactivated also is unable to
replicate the viral genome (10). Zta has homology to the bZIP
family of transcription factors whose general structure includes
a transactivation domain and a bZIP domain consisting of a
basic DNA contact region and a coiled-coil dimerization motif,
termed a leucine zipper (24, 49, 50). Zta has a more complex
dimerization domain than other bZIP family members, con-
sisting of a dimeric leucine zipper entwined with an adjacent
carboxyl-terminal region (35, 38, 44, 50). Zta is multifunc-
tional; through its basic region, it interacts with specific se-
quence DNA motifs (ZREs) that occur in the promoters of
several viral and cellular genes (49) and in the viral origin of
lytic replication (Ori-lyt) (46, 47). Through its bZIP domain,
Zta interacts with cellular transcription factors such as p53,
RAR, NF-B, CBP, and C/EBP (7), giving it the additional
ability to affect transcription without directly contacting DNA.
Zta also reprograms the host cell environment through its
bZIP domain by perturbing cell cycle control (6, 7, 11, 29, 39,
42, 43) and altering the expression of cellular genes (6, 7, 11,
30, 36, 37, 42, 43).
During this investigation, a global tandem affinity purifica-
tion (TAP) approach was used to identify host proteins that
interact with Zta. This resulted in the identification of the
nuclear protein 53BP1, a component of the ATM DNA dam-
age response pathway, as a novel binding partner. It has been
shown recently that signal transduction through the ATM
pathway is activated during EBV replication (23), and it was
suggested that replicating EBV genomes are recognized as
damaged DNA. Interestingly, other DNA and RNA viruses
activate DNA damage response pathways during their replica-
tion. Retroviruses and the murine gamma herpesvirus MHV68
are postulated to exploit this activation to aid replication (25,
48, 54, 57).
The relevance of the Zta-53BP1 interaction is investigated
with respect to the lytic replication of EBV.
MATERIALS AND METHODS
Cloning. An N-terminal TAP tag (provided by Tomoo Ogi and Alan Leh-
mann) containing protein A, the tobacco etch virus (TEV) protease cleavage site,
and calmodulin binding peptide (41) was inserted into pEGFP (BD Biosciences)
to replace the green fluorescent protein gene, generating CT212. The C-terminal
half of Zta (amino acids 133 to 245) was cloned C terminally to the TAP tag,
generating TAP-Tag Zta-bZIPCT. glutathione S-transferase (GST)-53BP1 fu-
sion proteins were used as described by Iwabuchi et al. (19).
Vectors used for the in vitro translation of Zta and expression in eukaryotic
cells have been described previously (16, 44, 51).
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The full-length human p27KIP1 coding sequence was subcloned into pRSETA
under the direction of the T7 promoter.
Full-length Zta was cloned into pCDNA3 (Invitrogen) using primers contain-
ing a histidine tag and EcoRI and BamHI restriction sites (5-CTGCACACCG
GGGATCCATGCATCATCATCATCATCATATGATGGACCCAATCGAC
TTCT-3 and 5-CTGCACACCGGGGAATTCTTAGAAATTTAAGAG ATC
CTCGTGTAA 3) to generate pCDNA3 HisZta.
TAP. HEK 293 cells (14) expressing Tap Zta were selected with G418. Zta and
associated proteins were purified using the method previously described by Puig
et al. in a HEPES-based buffer (40). The purified Zta complex was eluted and
analyzed by mass spectrometry by the University of Sussex Proteomics Centre.
Nickel pulldown and Western blotting. pCDNA3 or pCDNA3 HisZta was
transfected into Raji cells using Amaxa transfection technology according to the
manufacturer’s protocol. The solution V and program M-13 were used with 5 
106 cells and 2 g of DNA per electroporation. HEK 293 cells and HEK 293 cells
harboring a recombinant EBV plasmid with a deletion of the BZLF-1 gene
(designated HEK 293-BZLF1-KO) (10) were transfected using the Effectene
transfection reagent (Qiagen) with 2.5  106 cells and 10 g of DNA. Forty-eight
hours after transfection, the cells were washed and lysed in 500 l of TAP tag
lysis buffer. After three freeze-thaw cycles, the cell lysate was centrifuged at 2,000
rpm for 5 min before the supernatant was transferred to 200 l of His-select
nickel affinity gel (Sigma). The cell lysate and nickel resin were incubated to-
gether at 4°C overnight. The resin was washed three times and analyzed on a 3
to 8% Tris-acetate NuPAGE gel in Tris-acetate buffer (for 53BP1) or a 12%
Bis-Tris NuPAGE gel in morpholinepropanesulfonic acid (MOPS) buffer (for
Zta) (Invitrogen). Following sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE), proteins were transferred onto nitrocellulose
membranes and incubated with BZ1 antibody to Zta (60) or 53BP1 antibody
(BD Biosciences). Rabbit anti-mouse secondary antibody (DakoCytomation)
was incubated on the membrane, followed by incubation with horseradish
peroxidase-linked protein A (GE Healthcare). Proteins then were detected
by chemiluminescence.
Effect of knockdown of 53BP1 on EBV lytic cycle using siRNA. LCL#3 lym-
phoblastoid cells were seeded at 2  105/ml in Opti-MEM (Invitrogen). Small
interfering RNA (siRNA) duplexes (Invitrogen) were added to a final concen-
tration of 10 or 20 nM and admixed with the SiPort-neofx transfection reagent
(Ambion). siRNA was added at days 1 and 2. Cells were washed on day 3 and
placed in fresh OPTIMEM, and a further dose of siRNA was added. Cells were
harvested on day 4 for protein content, and the supernatant was harvested for
secreted virus. The sequences of the siRNA molecules were the following:
53BP1, 5UAUUACCGUCUCCUCGUUCTT and 5 GAACGAGGAGACGG
UAAUATT; control, 5 GGUGCGCUCCUGGACGUAGCCTT and 5GGCU
ACGUCCAGGAGCGCACCTT.
Protein expression was detected by Western blot analysis with a 53BP1-
specific antibody (ABCAM) and a glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH)-specific antibody (Ambion).
In vitro transcription and translation. RNA was synthesized using a Ribo-
MAX Large Scale RNA Production System kit (Promega). Treatment with
DNase was carried out to ensure no vector DNA was present and was used for
in vitro translation using wheat germ extract (Promega). Translated protein was
run on a 12% NuPAGE Novex Bis-Tris gel in MOPS buffer (Invitrogen) and
detected by phosphorimaging (STORM; Amersham). Samples subsequently
were diluted to ensure similar levels of labeled protein were present in each
reaction.
In vitro association assays. GST-53BP1 mutants were synthesized in BL21
pLysS bacteria (Invitrogen) as previously described (18, 19) and purified on
glutathione Sepharose (GE Healthcare) in phosphate-buffered saline (PBS).
Purified GST-53BP1 slurry was incubated with in vitro-translated protein diluted
(10 l in 360 l) in binding buffer and incubated for 2 h at 4°C. The beads were
washed and analyzed on a 12% NuPAGE Novex Bis-Tris gel in MOPS buffer
(Invitrogen). Proteins were detected by phosphorimaging (STORM; Amer-
sham).
Ability of Zta and mutants to activate EBV lytic cycle. HEK 293-BZLF1-KO
cells were transfected with pBABE vector, pBABEZta, or a pBABEZta mutant
using Effectene in a 6-well plate format (45). Cells (1  105) were seeded 1 day
prior to transfection, and 0.8 g of DNA was used. For RNA analysis, cells were
harvested after 48 h and total RNA was prepared. Gene expression was assayed
using quantitative PCR (qPCR) primers specific for BMRF1 and the host house-
keeping gene L32 as a control. For DNA, cells were harvested after 96 h and
lysed, and genomic DNA was prepared using a Wizard genomic DNA purifica-
tion kit (Promega) and then analyzed for EBV genome and human genome copy
numbers as described previously (12).
RESULTS
Identification of Zta-interacting cellular proteins. TAP was
used to undertake a global proteomic search for host proteins
that interact with Zta. The C-terminal 113 amino acids of Zta
containing the basic, zipper, and carboxyl-terminal regions was
fused to a protein A-calmodulin binding protein tag (called
Tap Zta) containing a TEV protease cleavage motif and was
expressed in epithelial cells (Fig. 1). Tap Zta protein was ex-
pressed at levels equivalent to those of Burkitt’s lymphoma
cells undergoing the EBV lytic cycle (Fig. 1B). Tap Zta and the
proteins associated with it were purified using immunoglobulin
affinity chromatography, released by TEV cleavage, and fur-
ther purified using calmodulin affinity chromatography. Tap
Zta-associated proteins were visualized by silver staining (Fig.
1C), and the location of the cleaved Tap Zta protein was
identified by Western blotting (Fig. 1D). Host proteins that
interact with Zta were identified using liquid chromatography-
coupled mass spectrometry (Fig. 1E). Proteins expected to
interact with one or another purification resin were identified
(calmodulin and immunoglobulins). In addition, three his-
tones, Ku70, Ku80, and mitochondrial transcription factor A,
as well as 53BP1, also copurify with Tap Zta. A recent study by
Wiedmer et al. also identified Ku70, Ku80, and histones as
proteins that copurify with Zta (58). Interestingly, none of the
previously reported proteins that functionally interact with Zta
were isolated in either system, namely p53 (62), RAR, RXR
(52), NF-B, C/EBP, CBP (1, 61), RACK1 (3), or TBP (33).
Thus, the interaction of Zta with the cellular proteins listed in
Fig. 1 appears to be either more stringent or more abundant in
these cells than its interactions with some previously reported
binding partners.
53BP1 interacts with Zta during viral replication in vivo.
The DNA damage response is activated during the replication
of EBV (8, 23) and is required for the replication of a related
gamma herpesvirus, MHV68 (54). It therefore is appealing
to speculate that the observed interaction between Zta and
53BP1 contributes to EBV replication.
To question whether 53BP1 is a bona fide binding partner of
Zta, in vivo protein association assays were carried out in two
cell systems containing EBV that were permissive to lytic re-
activation. HEK 293 cells harboring recombinant EBV with a
deletion of the BZLF-1 gene (HEK 293-BZLF1-KO) (10) were
used as an epithelial model, and an EBV-positive Burkitt’s
Lymphoma cell line (Raji), which is frequently used to analyze
early events in the EBV lytic cycle, was utilized as a B-lym-
phocyte model. HEK 293-BZLF1-KO cells are readily trans-
fected with lipofection-based reagents, whereas Raji cells are
less tractable but were amenable to the transfection of expres-
sion vectors following electroporation. Both cell lines were
transfected with an expression vector encoding a His-tagged
version of Zta, pCDNA3HisZta, to induce lytic cycle reactiva-
tion. Single-step purification on nickel resin was used to isolate
Zta and associated proteins and to question whether endoge-
nous 53BP1 interacted with full-length Zta during viral repli-
cation. Western blot analysis of the purified proteins revealed
that 53BP1 was present on the nickel resin from both HEK
293-BZLF1-KO and Raji cells following HisZta expression
(Fig. 2), indicating that 53BP1 interacts with Zta in both epi-
thelial cells and B lymphocytes. Lytic replication is known to
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stall in Raji cells prior to EBV genome replication (4, 64), and
in our hands, HEK 293-BZLF1-KO cells do not replicate the
EBV genome until 72 to 96 h after transfection with BZLF1
(data not shown). This suggests that the observed interaction
between Zta and 53BP1 observed 48 h after the transfection of
BZLF1 occurs during the early phase of the lytic cycle.
The BRCA1 C-terminal (BRCT) repeat region of 53BP1
binds to Zta in vitro. The interaction between Zta and 53BP1
may influence EBV replication. To question whether the in-
teraction is relevant, we attempted to identify mutants of Zta
that are compromised for their interaction with 53BP1 but
competent for other functions. The first step toward this goal
was to establish an in vitro assay to assess the interaction.
53BP1 is a large protein (1,972 amino acids); therefore, to
decipher which region of 53BP1 was required to bind to Zta,
an in vitro protein association assay was developed that used a
series of overlapping GST-tagged 53BP1 mutants (19) and
full-length Zta, which were generated using an in vitro trans-
lation system (51). These assays identified a region of 53BP1
contained within the 53BP1-BRCT construct that encompasses
the nuclear localization signal and the tandem BRCT repeats
(Fig. 3). The GST-53BP1-BRCT protein routinely associated
with 5% of the input proteins in these assays. As both Zta and
53BP1 can bind DNA, the potential exists that the interaction
that we observed between the two proteins in B cells is not due
to direct interaction but rather to a common interaction with
DNA. However, GST-53BP1-BRCT does not contain the
53BP1 DNA binding region of 53BP1, eliminating concern
over this potential artifact. An unrelated protein, p27KIP1, did
not bind to 53BP1 in the GST pulldown assay, confirming that
the interaction between 53BP1-BRCT and Zta was specific.
FIG. 1. Cellular proteins that copurify with Zta in vivo. (A) On the left is a schematic showing the current model for the structure of Zta bound
to DNA, and on the right it is shown in a linear form depicting the corresponding regions of Zta and the area used as bait for TAP. CT,
carboxy-terminal region. (B) Extracts from Tap Zta-expressing HEK 293 cells, or vector only (C), and immunoglobulin G (IgG)-induced Zta in
Akata cells, or nontreated cells (C), were fractionated on SDS-PAGE gels, and the relative expression of Tap Zta and Zta were determined by
Western blotting. Western blotting of CDK2 was used to determine loading equivalence. The panels showing induced Zta and Tap Zta were taken
from the same gel and were processed identically for both Zta and cdk2 staining. (C) Tap Zta and associated proteins were purified from HEK
293 cells using the tandem affinity approach, fractionated on an SDS-PAGE gel, and silver stained. (D) Tap Zta and associated proteins depicted
in panel C were fractionated on an SDS-PAGE gel, and Tap Zta was identified by Western blotting with a specific antibody. (E) A list of proteins
that copurified with the bZIPCT region of Zta and that were identified by mass spectrometry is shown, together with their accession numbers.
FIG. 2. 53BP1 association with Zta in vivo. HEK 293-BZLF1-KO
cells were transfected with pCDNA3 alone or with pCDNA3 HisZta
using Effectene transfection reagent. Raji cells were transfected with
the same constructs using Amaxa transfection technology. After 48 h,
cells were lysed and nickel agarose-associated proteins purified. Sam-
ples were analyzed by Western blotting for 53BP1 (top) and Zta
(bottom), as indicated. Proteins then were detected by chemilumines-
cence.
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Further experiments with just the C-terminal 113 amino acids
of Zta present in Tap Zta also confirmed the interaction (data
not shown).
The C-terminal region of Zta is responsible for 53BP1 bind-
ing. The in vivo and in vitro association assays established that
the region of Zta responsible for the interaction with 53BP1 is
located in the carboxy-terminal half of the protein, between
amino acids 133 and 245. Subsequent studies to refine the
region(s) of Zta required for the interaction with 53BP1 used
a series of carboxyl-terminal termination mutants of Zta (Fig.
4) (44). These 35S-labeled truncated proteins were generated
using an in vitro translation system and were applied to the in
vitro association assay with GST-tagged 53BP1-BRCT. The
purification of the 53BP1/Zta complexes revealed that the re-
moval of the three extreme C-terminal amino acids of Zta
(designated ZtaL243ter) was sufficient to considerably reduce
Zta binding to 53BP1-BRCT (Fig. 4). The removal of a further
five amino acids (ZtaV237ter), or more substantial deletions,
completely abrogated the interaction. This demonstrates that
the carboxyl-terminal region of Zta contributes to the interac-
tion of Zta with 53BP1.
The absolute conservation of the C terminus of Zta in all
isolates of EBV that have been examined to date (15, 17, 21)
suggests that this region of Zta is functionally relevant; how-
ever, interaction with 53BP1 is the first role that has been
ascribed to it.
The interaction between 53BP1 and Zta is not required for
basic DNA binding or transactivation functions of Zta. The
identification of the Zta mutants that are compromised in their
ability to interact with 53BP1 provides a potential route to
address the importance of the 53BP1-Zta interaction in vivo,
should they retain basic functions of Zta. The ability of the Zta
termination series to form functional dimers and interact with
DNA has been reported previously (44) and is summarized in
Fig. 5. Importantly, four of the mutants from this series that
are compromised for interaction with 53BP1 (ZtaL243ter,
ZtaV237ter, Zta234ter, and Zta231ter) are able to form
dimers and to interact with DNA (44). Here, we assessed the
ability of the Zta mutants to transactivate the expression of a
known target on the latent EBV genome in HEK 293-
FIG. 3. 53BP1 association with Zta in vitro. (A) Schematic showing
known motifs in the BRCT region of 53BP1, a nuclear localization
sequence (NLS; gray filled box), and two BRCA1 C-terminal domains
(BRCT; black boxes). (B) In vitro associations between GST and
GST-53BP1-BRCT and in vitro-translated Zta were determined in
GST binding buffer. The left lane shows in vitro-translated protein
added to the reaction mixture (marked Input). The remaining three
lanes show any association Zta makes with the indicated GST proteins.
(C) The same experiment as that described for panel B was carried out
with in vitro-translated human p27KIP1 as a control.
FIG. 4. C-terminal region of Zta is important in 53BP1 binding in vitro. (A) Schematic diagram showing part of the Zta sequence with the
location of the Zta termination mutants indicated above the zipper and C-terminal regions. The zipper region is shown by a gray box, and the
carboxyl-terminal region is shown by the black box below the sequence. (B) The indicated in vitro-translated proteins were generated in wheat germ
extract. Zta and its termination mutants were analyzed by SDS-PAGE on a 12% gel and quantitated after detection using phosphorimaging.
(C) Equivalent quantities of in vitro-translated proteins, indicated above each lane, were incubated with GST-53BP1-BRCT-Sepharose or GST,
as indicated, and the Zta that associates is shown.
FIG. 5. Zta mutants that are defective for binding to 53BP1 retain
the ability to form dimers, bind DNA, and transactivate an EBV gene.
(A) Schematic diagram summarizing the ability of the Zta termination
mutant to form dimers, bind DNA, and activate the expression of
BMRF1 from the endogenous EBV genome. (B) The indicated Zta
mutants were expressed in HEK 293-BZLF1-KO cells, and 48 h later
RNA was prepared and the amount of BMRF1 RNA relative to the
expression of a control cellular gene and each Zta mutant was deter-
mined using a series of qPCR assays. The relative expression of
BMRF1 is indicated, together with the standard errors from replicate
experiments.
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BZLF1-KO cells (Fig. 5B). All of the mutants that can bind
DNA retain the ability to transactivate the expression of the
viral gene BMRF-1 in this system. This reveals that those mu-
tants of Zta that are compromised in their interaction with
53BP1 retain the characteristics of DNA binding and transac-
tivation.
The ability to activate the viral lytic cycle correlates with the
ability to interact with 53BP1. To assess whether the interac-
tion between 53BP1 and Zta affected the ability of Zta to
induce the viral lytic cycle, we questioned whether viral ge-
nome replication was affected by the termination mutants. The
Zta mutant series was introduced into HEK 293-BZLF1-KO
cells by transfection, and the EBV genome load within the cells
was determined subsequently using qPCR (Fig. 6). A basal
level of EBV DNA was detected in all cells due to the presence
of latent EBV genomes, which is represented in the circular
episomal form in Fig. 6. The expression of full-length Zta was
anticipated to activate EBV lytic replication, resulting in an
accumulation of EBV genomes within cells en route to their
secretion as virions, as represented by linear EBV genomes.
The expression of Zta successfully activated EBV genome rep-
lication, measured as an increase in intracellular genome ac-
cumulation. However, the deletion of the final three carboxyl-
terminal amino acids of Zta was sufficient to abolish EBV
genome replication in this system. The clear correlation be-
tween the compromised interaction of Zta mutants with 53BP1
and the loss of their ability to activate the EBV lytic cycle, as
measured by lytic genome replication, demonstrates a role for
the Zta interaction with 53BP1 for the EBV lytic cycle. The
precise step in viral replication that requires this interaction
remains to be determined.
Knockdown of 53BP1 expression reduces lytic replication.
To further question the relevance of 53BP1 for EBV replica-
tion, we examined the effect on viral replication of knocking
down 53BP1 expression using siRNA. LCL#3 cells were cho-
sen for this study. A small proportion of these cells spontane-
ously initiate the viral lytic cycle at any one time. siRNA di-
rected against 53BP1 or a control gene was introduced into
LCL#3 cells for a 4-day period. This approach achieved a
decrease in 53BP1 protein abundance in the cells (Fig. 7).
Virion DNA released from the cells between days 3 and 4 was
prepared, and the amount of viral DNA was quantitated using
qPCR. A substantial reduction in EBV was found that corre-
lated with the knockdown of 53BP1 expression in these cells
(Fig. 7).
DISCUSSION
During the EBV lytic cycle, 80 or so viral genes are ex-
pressed, and the EBV episomal DNA is replicated via long
linear double-stranded DNA molecules that subsequently are
cleaved into genome-length units during packaging into virions
(55). Zta is critical for this process, acting as a transcriptional
activator and a replication factor and by perturbing host signal
transduction and cell cycle regulation (49). The interaction
that we identify here between Zta and the host protein 53BP1
implies a direct connection with the DNA damage response.
Using a combination of viral mutants and the knockdown of
gene expression, we show that the interaction of Zta with
53BP1 is important for EBV lytic cycle replication.
This publication also demonstrates that the extreme car-
boxy-terminal end of Zta (L243-F245) is required for viral
replication. No functions previously had been ascribed to this
region, although a recent publication revealed a role for the
interaction between position D236 in the C-terminal tail and
the zipper for the viral lytic cycle (32).
53BP1 is intimately involved in the DNA damage response
induced by exposure to ionizing radiation. It rapidly relocalizes
within cells to form distinct foci on damaged DNA. It is phos-
phorylated by ATM and forms multicomponent complexes
that include phosphorylated H2AX and components of the
MRN complex (20, 26). The precise function of the complex is
unknown; however, as 53BP1 has no known catalytic activity,
the hypothesis that it acts as a scaffold to bring other compo-
FIG. 6. C-terminal region of Zta is defective for EBV replication.
(A) A schematic diagram represents the latent EBV genome as a
circular episome and lytic replication induced by Zta generating linear
molecules both within cells and outside cells packaged as virions.
(B) Zta and the indicated Zta termination mutants were expressed in
HEK 293-BZLF1-KO cells and harvested after 96 h. Cells were ana-
lyzed for EBV genome and human genome copy numbers. The graph
shows the levels of EBV genome present (relative to those of the
human genome) taken from duplicate experiments, with the standard
errors shown.
FIG. 7. 53BP1 contributes to EBV genome replication. siRNA du-
plexes directed against 53BP1 or a control (con) duplex (10 nM) were
introduced into LCL#3 cells for 4 days. (A) The effect of each siRNA
on 53BP1 protein expression and the expression of the protein en-
coded by the housekeeping gene GAPDH were monitored by the
Western blot analysis of cell extracts with specific antibodies as indi-
cated. (B) Supernatant from the cells was harvested, and the amount
of EBV genome in virions was determined by the qPCR detection of
the EBV genome.
11120 BAILEY ET AL. J. VIROL.
 o
n
 N
ovem
ber 15, 2017 by UNIV O
F SUSSEX
http://jvi.asm.org/
D
ow
nloaded from
 
nents into close proximity provides a working model to account
for its clear role in the DNA damage response.
The region of 53BP1 that associates with Zta contains two
BRCT regions. Repeat units of this domain are present in
many DNA repair and checkpoint-associated proteins (5).
The domains can provide phosphorylation-dependent protein-
docking functions that may be involved in the recruitment of
proteins to nuclear foci following DNA damage (28). Intrigu-
ingly, the BRCT region of 53BP1 also is involved in a phos-
phorylation-independent interaction with p53 (9, 22). This is of
interest, as both Zta and 53BP1 are able to interact with p53
independently (18, 63) to generate a local environment in
which cross-regulation may be enhanced.
The involvement of 53BP1 in EBV lytic replication is par-
ticularly intriguing, as the replication of the EBV genome
generates at least one exposed DNA end, which is the start of
the newly replicating linear DNA. No protection mechanism is
known to shield the newly replicating viral DNA, and poten-
tially more exposed unprotected ends are generated following
the cleavage of the replicated DNA to generate the unit-length
viral genomes during packaging into virions. During such cir-
cumstances, it would be advantageous for EBV to manipulate
any resultant DNA damage response.
During EBV replication, signal transduction through ATM
is activated, resulting in the phosphorylation of H2AX, ATM,
Chk2, and p53 and the recruitment of the MRN complex (8,
23). The potential danger to EBV of activating the ATM signal
transduction pathway is the probability that signal transduction
through ATM would prime attempts to repair the newly rep-
licated ends of viral DNA, resulting in structures that either do
not generate viable virus or promote programmed cell death.
However, in EBV-positive cells, signal transduction falls short
of the expected activation of downstream targets such as
p21CIP1 (26). The relevance of the activation of the ATM
pathway for EBV replication was questioned previously, using
caffeine to inhibit signal transduction. In that study, the en-
forced expression of Zta was employed to activate viral repli-
cation in a marmoset cell line (23). Surprisingly, no effect of
caffeine on viral replication was detected, suggesting that ATM
activation was not required for viral replication.
The complexity of the interaction of gammaherpesviruses
with the DNA damage response increased with the discovery
that H2AX, a key component of the DNA damage response
pathway, plays an important role in the replication of the
related gammaherpesvirus MHV68 (54). H2AX is directly
phosphorylated by MHV68 protein kinase (vPK) and is re-
quired for viral replication in some cell lineages (54, 59). In-
terestingly, the EBV homologue of vPK, BGLF4, coassociates
with Zta (2) and may provide a link between H2AX and EBV
replication: it is found in viral replication compartments (56),
it is essential for viral replication (13), and it is able to directly
phosphorylate H2AX (54). Thus, H2AX is an additional can-
didate on this pathway that may modulate EBV replication,
but its potential is unproven.
Our conclusions that 53BP1 expression and 53BP1-Zta in-
teraction aids or may even be required for viral replication
suggest that the activation of ATM that occurs is detrimental
to virus replication, and that the interaction between Zta and
53BP1 reduces or negates this. This may be complemented by
the ability of Zta to neutralize the function of p53, a down-
stream effector of ATM that is required to drive apoptosis (30,
31, 63).
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